$NEUP News

HC Wainwright & Co. Downgrades Neuphoria Therapeutics to Neutral

Neuphoria Therapeutics Q3 EPS $(0.09) Beats $(0.97) Estimate

Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation

Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees

HC Wainwright & Co. Maintains Buy on Neuphoria Therapeutics, Lowers Price Target to $7

Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium

Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders

Neuphoria Therapeutics 13D Filing Shows Lynx1 Capital Management LP Boosts Stake To 16.3% And Submits Revised $4.75-Per-Share Buyout Proposal For Neuphoria Therapeutics

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

Neuphoria Initiates Strategic Alternatives Review; Co. Also Confirms Receipt Of Unsolicited Indication Of Interest From Lynx1 Master Fund LP To Acquire All Outstanding Shares It Does Not Already Own For $5.20/Share

Neuphoria Initiates Strategic Alternatives Review; Co. Also Confirms Receipt Of Unsolicited Indication Of Interest From Lynx1 Master Fund LP To Acquire All Outstanding Shares It Does Not Already Own For $5.20/Share

Is Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Worth US$4.4 Based On Its Intrinsic Value?

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan To Protect Integrity Of Process; Board Declares Dividend Of One Preferred Share Purchase Right For Each Outstanding Share Of Co

Neuphoria Therapeutics shares are trading higher. Shareholder Weston Nichols reported purchase of 639,110 shares of Neuphoria Therapeutics at average price of $5.14/share in Form 4 filing on Thursday.

Neuphoria Therapeutics Shares Resume Trade

Neuphoria Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 104.94%